Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · October 21, 2015

Modified Docetaxel, Cisplatin, and Fluorouracil for Metastatic Gastric Adenocarcinoma

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium
J. Clin. Oncol 2015 Oct 14;[EPub Ahead of Print], MA Shah, YY Janjigian, R Stoller, S Shibata, M Kemeny, S Krishnamurthi, YB Su, A Ocean, M Capanu, B Mehrotra, P Ritch, C Henderson, DP Kelsen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading